Jaffetilchin Investment Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jaffetilchin Investment Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$397K	Sell	3,110 -7	-0.2%	-$874	0.02%	305
2025 Q4	$380K	Buy	3,117 +447	+17%	+$51.3K	0.02%	311
2025 Q3	$268K	Sell	2,670 -35	-1%	-$3.15K	0.02%	383
2025 Q2	$224K	Sell	2,705 -1,366	-34%	-$109K	0.01%	391
2025 Q1	$330K	Buy	4,071 +1	+0%	+$89	0.02%	311
2024 Q4	$367K	Sell	4,070 -380	-9%	-$36.8K	0.03%	276
2024 Q3	$440K	Buy	4,450 +166	+4%	+$16.3K	0.03%	248
2024 Q2	$397K	Buy	4,284 +1,390	+48%	+$125K	0.03%	246
2024 Q1	$275K	Buy	2,894 +354	+14%	+$32.8K	0.02%	302
2023 Q4	$227K	Buy	+2,540	New	+$189K	0.02%	313

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jaffetilchin Investment Partners's XBI Position: Q1 2026 in Review

Jaffetilchin Investment Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.22% in Q1 2026, selling an estimated $874 and leaving 3,110 shares worth $397K. The position accounts for 0.02% of the portfolio, ranked #305.

Jaffetilchin Investment Partners first reported a position in XBI in Q4 2023 and has held it in 10 quarters since. The position peaked at $440K in Q3 2024. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Jaffetilchin Investment Partners held 3,110 shares of State Street SPDR S&P Biotech ETF worth $397K as of Q1 2026.
Jaffetilchin Investment Partners sold 7 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $874.
State Street SPDR S&P Biotech ETF made up 0.02% of Jaffetilchin Investment Partners's portfolio in Q1 2026, its #305 holding.
Jaffetilchin Investment Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 10 quarters since.
Jaffetilchin Investment Partners's State Street SPDR S&P Biotech ETF position peaked at $440K in Q3 2024.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Jaffetilchin Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.